February 2005

  

"ISPOR e-BULLETIN" provides updates of recent ISPOR activities and events. For detailed information on ISPOR activities, members are encouraged to go to www.ispor.org.

 

Please share these new ISPOR activities with your colleagues.

  eBulletin Index

February 200

 

  

ISPOR e-BULLETIN provides updates of recent ISPOR activities and events. For detailed information on ISPOR activities, members are encouraged to go to www.ispor.org.

 

Please share these new ISPOR activities with your colleagues.

 

NEW THIS MONTH

 

**NEW**    ISPOR 10th Annual International Meeting Updates (25% increase in abstract submissions!)

**NEW**    ISPOR Celebrates 10-Year Anniversary

**NEW**     Value in Health Vol. 8 No. 1 (January/February 2005)

**NEW**    Symposium: The Evolution and Innovation of Pharmaceutical Technology: Implications for US Medicare Modernization Act

**NEW**    Symposium: Methodological Issues In The Analysis Of Health Care Databases

**NEW**    5 New Modules on Pharmacoeconomics in Drug Development, Reimbursement, and Marketing

**NEW**    12 New Positions At The ISPOR Website

**NEW**    Clinical Practice and Patient Registry SIG Move Forward

**NEW**    New ISPOR Task Force: Using ‘Real World’ Data in Coverage and Reimbursement Decisions Identify Issues

**NEW**    Retrospective Database and Risk Management SIG Take Action

 

ISPOR ONGOING ACTIVITIES

 

1.       Publications

2.       Meetings and Congresses

3.       Educational Activities

4.       Student News

5.       ISPOR Special Interest Groups

6.       Committee and Task Force Activities

7.       Hot Topics

8.       Important Dates to Remember

9.       Employment in Pharmacoeconomics and Outcomes Research

10.    Membership

 


  1. PUBLICATIONS

Top

 

VALUE IN HEALTH

 

Value in Health: Volume 8, Issue 1, January/February 2005 is online and available this month at: http://www.ispor.org/valueinhealth_index.asp.  The following is the TABLE OF CONTENTS for Value in Health Volume 8, Issue 1, January/February 2005:

 

EDITORIAL

Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter Uncertainty

Andrew Briggs

 

POLICY APPLICATION

Growth and Quality of the Cost-Utility Literature, 1976-2001

Peter J. Neumann, Dan Greenberg, Natalia V. Olchanski, Patricia W.

Stone, Allison B. Rosen

 

Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability

Marco Barbieri, Michael Drummond, Richard Willke, Jeremy Chancellor, Bruno Jolain, Adrian Towse

 

EMPIRICAL

An Evaluation of Managing and Educating Patients on the Risk of Glucocorticoid-Induced Osteoporosis

Randy P. McDonough, William R. Doucette, Patty Kumbera, Donald G.

Klepser

 

Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries

Jan B. Oostenbrink, Maureen P.M.H. Rutten-van Molken, Brigitta U. Monz, J. Mark FitzGerald

 

METHODOLOGY

Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy

Leon E. Cosler, Visaharan Sivasubramaniam, Olayemi Agboola, Jeffrey Crawford, David Dale, Gary H. Lyman

 

An Assessment of the Impact of Informative Dropout and Nonresponse in Measuring Health-Related Quality of Life Using the EuroQol (EQ-5D) Descriptive System

Julie Ratcliffe, Tracey Young, Louise Longworth, Martin Buxton

 

Development and Initial Validation of an Instrument to Measure Physician-Pharmacist Collaboration from the Physician Perspective

Alan J. Zillich, William R. Doucette, Barry L. Carter, Clarence D.

Kreiter

 

Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future for Piggyback Evaluations?

Amy K. O'Sullivan, David Thompson, Michael F. Drummond

 

CORRESPONDENCE

Some Considerations for the Interpretation of Health-Related Quality of Life Data

 

Needs-Based Health-Related Quality of Life Measurement: New Wine in Old Bottles?

 

Needs-Based Quality of Life (QoL): More Clarity than Claret!

 

Thresholds in Cost-Effectiveness Analysis-More of the Story

 

 

ISPOR CONNECTIONS

 

ISPOR CONNECTIONS: Volume 10, Issue 6, November/December 2004 is now available to the public at: http://www.ispor.org/news/index_new.asp.  In this issue:

 

ISPOR 9th Annual Meeting Summary

ISPOR 9th Annual Meeting Short Courses

ISPOR 9th Annual Meeting Award Recipients

ISPOR 9th Annual Meeting Photo Gallery

 

 

HEALTH CARE COST, QUALITY, AND OUTCOMES: ISPOR BOOK OF TERMS

 

"The ISPOR Book of Terms has been a real hit with our customers and employees alike.  It fills a gap for those who are new to Outcomes." Jenifer Ehreth, PhD, Director Reimbursement for Europe, Middle East and Africa Medtronic Europe

 

This ISPOR publication includes more than 100 detailed monographs covering over 400 terms used in health care delivery, management, and regulation, as well as health care outcomes research including clinical, economic, and quality-of-life research terms. ISPOR member discounted price is $36.00; a 40% discount!  Student/Library/Academic discounted price: $33.00 (a 45% discount). On-line ordering is now available at: http://www.ispor.org/publications/lexicon_index.asp.  Contact Stephen Priori at spriori@ispor.org for information on orders over 1000. 


  

  1. ISPOR MEETINGS AND CONGRESSES

Top

   

**NEW**ISPOR 10TH ANNUAL INTERNATIONAL MEETING

     May 15-18, 2005, Marriott Wardman Park Hotel, Washington, DC, USA

 

There was an astounding 25% increase in abstract submissions for the ISPOR 10th Annual International Meeting!!!!! The estimated number of presentations is as follows: 26 contributed workshop presentations, 10 contributed issues panel presentations, 64 contributed podium presentation, and over 400 contributed poster presentations.

 

Early Registration Deadline: 19 April 2005

 

HOTEL RESERVATIONS, online reservations and additional information:

http://www.ispor.org/meetings/washington0505/hotel.asp

 

MEETING AT A GLANCE

http://www.ispor.org/meetings/washington0505/index.asp

 

EXHIBIT SPACE, contract available online at:

 

SPONSORSHIP Opportunities are available, for more information go to:

 

SYMPOSIUM: Evolution and Innovation of Pharmaceutical Technology: Implications for US Medicare Modernization Act co-sponsored by ISPOR and the PhRMA Health Outcomes Committee

Sunday, May 15, 2005, 5:00-7:00PM

Marriott Wardman Park Hotel, Washington DC, USA (Prior to the ISPOR 10th Annual International Meeting)

The symposium will highlight progress in hypertension, elevated cholesterol, diabetes, congestive heart failure, asthma, and depression over the past 40 years and link changes in therapeutic guidelines.

Moderator:  Joseph Jackson PhD, Group Director, Health Economic Policy and External Relations, Bristol-Myers Squibb, Princeton, NJ, USA
Evolution and Innovation in Pharmaceutical Therapy

Speaker: Robert Dubois, MD, PhD, Senior Vice President, Cerner Health Insights, Beverly Hills, CA, USA

Implications for US Medicare Modernization Act

Speaker: TBD

 

SYMPOSIUM: Methodological Issues In The Analysis Of Health Care Databases sponsored by: IMS Health

Monday, May 16, 2005, 1:00-2:00PM

Marriott Wardman Park Hotel, Washington DC, USA (During the ISPOR 10th Annual International Meeting)

During this symposium, presentations and discussion of issues in the analysis of health care databases in the areas of design and patient selection as well as statistical analyses will be presented. Specific topics like control for known and unknown variables that may affect the outcome of interest and how to handle missing data will be discussed..

 

**NEW**  JOIN US IN CELEBRATING THE ISPOR 10th ANNIVERSARY !!

 

ISPOR celebrates its 10-Year Anniversary though out the 10th Annual International Meeting!  The schedule of celebratory events is as follows:

 

MONDAY, MAY 16

8:00-8:30 AM ISPOR: 10 YEARS – “PAST, PRESENT AND FUTURE

 

12:30–2:00 PM ISPOR 10 YEARS CELEBRATION CAKE CUTTING CEREMONY

 

6:00-8:00PM ISPOR 10th ANNIVERSARY PARTY PRIZES AND TOASTS

 

TUESDAY, MAY 17

10:45-11:15 AM 10 YEAR MEMBERS' RECOGNITION

 

12:30PM–1:30PM ISPOR 10 YEARS CELEBRATION PRIZES

 

5:00-7:00PM ISPOR 10th ANNIVERSARY PARTY    

 

7:30- 10:30 PM ISPOR 10th ANNIVERSARY PARTY AT THE Sequoia Restaurant on the Potomac River, open bar & food, DJ and dance floor, door prizes, quiz games, transportation to/from the Marriott Wardman Park Hotel, Only $50 USD

 

WEDNESDAY, MAY 18

10:30- 11:00AM ISPOR 10 YEARS PAST PRESIDENTS’ RECOGNITION

 

 

ISPOR 10 Year History

 

 

The International Society for Pharmacoeconomics and Outcomes Research is an international organization promoting the science of pharmacoeconomics and health outcomes research. The Society was established in 1995 under the prior name Association of Pharmacoeconomics and Outcomes Research (APOR), until 1997 when it became International. The Society was organized to act as a scientific leader relevant to research in pharmacoeconomics, health outcomes assessment, and related issues of public policy. It represents healthcare researchers and practitioners including pharmacists, physicians, economists, nurses and researchers from academia, pharmaceutical industry, government, managed care, health research organizations, and purchasers of health care.

 

1995: APOR established and first issue of APOR NEWS published.

 

1996: APOR First Annual International Meeting held in Philadelphia, PA USA.

 

1997: APOR 2nd Annual International Meeting; APOR Lipid Conference, Orlando, Fl, USA; ISPOR merged with International Society for Economic Evaluation of Medicines (ISEEM) to form ISPOR; website launched.

 

1998: ISPOR 3rd Annual International Meeting; ISPOR Inaugural European Conference, Cologne, Germany; Pharmacoeconomics-Identifying the Issue Conference; ISPOR first issue of Value in Health Journal published, APOR NEWS renamed ISPOR NEWS; ISPOR LEXICON, First Edition published, first ISPOR Student Chapter established (University of Texas).

 

1999: ISPOR 4th Annual International Meeting; ISPOR 2nd Annual European Conference, Edinburgh, Scotland; Rising Cost of Drug Coverage and Limited Healthcare Budgets: A Search for Solutions Conference, Washington, DC.

 

2000: ISPOR 5th Annual International Meeting; Quality of Life Symposium; ISPOR 3rd Annual European Conference, Antwerp, Belgium.

 

2001: ISPOR 6th Annual International Meeting; NICE to Know: An Update on the National Institute for Clinical Excellence Guidelines Symposium; ISPOR 4th Annual European Congress, Cannes, France; Value in Health Journal indexed in MEDLINE (Vol. 4, Issue Jan/Feb 2001).

 

2002: ISPOR 7th Annual International Meeting; Patient-Reported Outcomes ‘PRO’ Symposium: Conceptual and Methodological Issues Symposium; ISPOR 5th Annual European Congress, Rotterdam, The Netherlands; ISPOR NEWS renamed ISPOR CONNECTIONS.

 

2003: ISPOR 8th Annual International Meeting; Pharmacoeconomics in a Managed Care Environment: Opportunities & Challenges Symposium; ISPOR 6th Annual European Congress, Barcelona, Spain; ISPOR First Asia Pacific Conference, Kobe Japan; Clinical & Social Burden of COPD Symposium; Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms published.

 

2004: ISPOR 9th Annual International Meeting; Benefit/Risk: In Search of the Proper Balance Symposium; ISPOR 7th Annual European Congress, Hamburg, Germany; ISPOR eBulletin first published;  ISPOR Distance Learning modules established, ISPOR Managed Care Outcomes Research Database and Pharmacoeconomics Around the World database established.

 

2005: ISPOR 10th Annual International Meeting; The Evolution and Innovation of Pharmaceutical Technology: Implications for US Medicare Modernization Act Symposium; ISPOR 8th Annual European Congress, Florence, Italy; ISPOR Research Digest established.

 

 

 


 

  1. EDUCATION ACTIVITIES

Top

           

ISPOR SHORT COURSES

Saturday, May 14th & Sunday May 15th, 2005 - Prior to the ISPOR 10th Annual International Meeting

 

For short course descriptions and faculty information go to:

·       Saturday, May 14th: http://www.ispor.org/meetings/washington0505/sc14.asp

·        Sunday, May 15th: http://www.ispor.org/meetings/washington0505/sc15.asp

 

 

Pharmacoeconomics Courses:

·        Pharmacoeconomics for Decision-makers – Saturday Full Day Course (8:00am-5:00pm)

·      Elements of Pharmaceutical Pricing – Sunday Morning Course (8:00am-12:00pm)

 

Clinical Assessment Courses:

·        Retrospective Database Analysis: Econometric Methods – Sunday Full Day Course (8:00am-5:00pm)

·      Meta-Analysis and Systematic Literature Review – Sunday Morning Course (8:00am-12:00pm)

 

Modeling Courses:

·        Bayesian Analysis: Overview – Saturday Morning Course (8:00am-12:00pm)

·        Bayesian Analysis: Applications – Saturday Afternoon Course (1:00pm-5:00pm)

·      Modeling: Structure & Design of Model – Sunday Full Day Course (8:00am-5:00pm)

·      Discrete Event Simulation for Economic Analyses - Sunday Afternoon Course (1:00pm-5:00pm)

·      Introduction to Decision Analysis – Sunday Afternoon Course (1:00pm-5:00pm)

 

Quality of Life/Patient-reported Outcomes Courses:

·        Introduction to Quality of Life/Patient-Reported Outcomes – Saturday Afternoon Course (1:00pm-5:00pm)

·       Old and New Utility Measures in Health Economics and Outcomes Research – Sunday Morning Course (8:00am-12:00pm)

·       Advanced Quantitative Methods for Quality of Life/Patient-reported Outcomes Research – Sunday Afternoon Course (1:00pm-5:00pm)

 

Economic Analysis Courses:

·        Financial Impact / Cost of Illness – Saturday Afternoon Course (1:00pm-5:00pm)

·     Cost Estimation: Finding and Extracting Cost Data – Sunday Morning Course (8:00am-12:00pm)

·     Statistical Considerations in Economic Evaluations – Sunday Afternoon Course (1:00pm-5:00pm)

 

ISPOR Distance Learning Program Modules

ISPOR Distance Learning Program

 

**NEW**Modules on Pharmacoeconomics in Drug Development, Reimbursement and Marketing

·       Pharmacoeconomics in Drug Development and Marketing: An Overview      

·       Drug Development - Pre-Phase II Pharmacoeconomic Activities

·       Drug Development- Phase II Pharmacoeconomic Activities

·       Drug Development – Phase III Pharmacoeconomic Activities

·       Drug Development – Phase IIIB and Pre-Market Entry Pharmacoeconomic Activities

 

The following module topics are currently available:

·       Pharmacoeconomics

·       Pharmacoeconomic Evaluations &  Methods

·       Cost-Effectiveness Analysis

·       Cost-Benefit Analysis

·       Cost-Utility Analysis

·       Humanistic Outcomes (Utilities, Health-related Quality of Life, Patient-reported Outcomes, Patient Preferences)

·       Study Design in Pharmacoeconomics

·       Guidelines and Reference Standards

 


 

  1. STUDENT NEWS

Top

 Visit ISPOR Internship- Professional Recruitment Assistance Program (I-PRAP)

STUDENTS have the opportunity to search for internship positions available and post their CVs/resumes for employers to view. Post your CV today!

EMPLOYERS have the opportunity to access CVs/resumes from interested students.
 

For more details on the ISPOR Student Network, please visit: http://www.ispor.org/student/student_index.asp

          


  

  1. ISPOR SPECIAL INTEREST GROUPS (SIG)

Top

 

MEDICATION COMPLIANCE SIG

 

**NEW**The Issues and Methods Definitions Working Group thanks all members who commented on the proposed consensus definitions of Medication Compliance (Synonym Adherence) and Medication Persistence.  The Group is now considering the comments and working on operationalizing the definitions. For more details on this SIG, please visit: http://www.ispor.org/sigs/medication.asp

 

CLINICAL PRACTICE SIG

 

The Clinical Practice SIG submitted ISSUES PANEL and 2 WORKSHOPS for presentation at the 10th Annual Meeting.For more details, please visit: http://www.ispor.org/sigs/sigsindex.asp

 

PATIENT REGISTRY SIG

 

Patient Registry Survey: Thanks to the all the ISPOR members who responded to the survey.  The analysis is complete and the results will be published in ISPOR CONNECTIONS shortly. For more details on this SIG, please visit: http://www.ispor.org/sigs/patient_registr.asp

 

RETROSPECTIVE DATABASE SIG

 

Co-Chairs:
Michael Johnson PhD
, Houston Center for Quality of Care and Utilization Studies, Michael E. DeBakey VA Medical Center, Assistant Professor of Medicine, Baylor         College of Medicine       
William D. Marder PhD,
Senior Vice President & General Manager, Medstat

 

Working Group Co-Chairs: 

Research Design & Analysis: 
Rajesh Balkrishnan MS, PhD, Ohio State University College of Pharmacy and School of Public Health, Columbus, Ohio, USA
Samuel Wagner BSc
, PhD, RPh, Pfizer, Inc. Aubrey, TX, USA

Policy Advocacy: 
Christian Gericke
MD, MSc, Berlin University of Technology, Berlin, Germany
Mohamed Hussein MSc, HUMANA, Louisville, KY, USA

Database Development: 
Benoit Tano
MD, PhD, John Hopkins Asthma and Allergy Center, Baltimore, MD, USA Bradley Martin PharmD, PhD, RPh, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Classification of Databases: 
Gordon Cummins
MS, HealthCore, Inc., Wilmington, DE, USA
Carl Asche MBA, MSc, PhD, University of Utah, Salt Lake City, UT, USA

For more details on this SIG, please visit: http://www.ispor.org/sigs/retrospective_db.asp

 

RISK MANAGEMENT SIG

 

Chair:  Dennis Raisch RPh, PhD, Associate Director, VA Cooperative Studies Program, Clinical Research Pharmacy, Albuquerque, NM, USA

 

Working Group Chairs:

Identification of Risk & Benefits Working Group

Co-Chair: Larry Liu MD, PhD, Director, Anti-Infectives US Outcomes Research, Pfizer, New York, NY, USA

Co-Chair: Nicholas Lipskiy PhD, MBA, Director or Biostatistics, Surveillance Data Inc, Plymouth Meeting, PA, USA

Communication Working Group

Co-Chair: Ateequr Rahman MBA, PhD, Assistant Professor, College of Pharmacy, Shenandoah University, Winchester, Virginia, USA

Co-Chair: Paul Stang, PhD, MS, Executive Vice President, Galt Associates, Blue Bell, PA, USA

Interventions/Implementation Working Group

Co-Chair: Anthony Lockett MBA, MD, PhD, Medical Director OHI, Leeds, W. Yorkshire, UK

Co-Chair: Paul Stang, PhD, MS, Executive Vice President, Galt Associates, Blue Bell, PA, USA

 

For more details on this SIG, please visit: http://www.ispor.org/sigs/rm.asp

 

QUALITY OF LIFE SIG

For more details on this SIG, please visit: http://www.ispor.org/sigs/qol.asp

 

HEALTH TECHNOLOGY ASSESSMENT SIG

For more details on this SIG, please visit: http://www.ispor.org/sigs/hta.asp

 

MANAGED CARE SIG

 For more details, please visit: http://www.ispor.org/sigs/sigsindex.asp

 

Special Interest Group membership is open to ALL ISPOR members. To JOIN any SIG: http://www.ispor.org/sigs/joinsig.htm

 


 

 

  1. ISPOR BOARD, COMMITTEE, AND TASK FORCE ACTIVITIES

Top

           

AWARD COMMITTEE ACTIVITIES

 

ISPOR RESEARCH EXCELLENCE AWARDS CALL FOR NOMINATIONS

 

The ISPOR Awards Committee is seeking nominees for both the ISPOR Research Excellence Award for Methodology Excellence and Research Excellence Award for Practical Application Excellence. See http://www.ispor.org/awards/methodology_.asp and http://www.ispor.org/awards/application_.asp for Excellence Awards descriptions, criteria, selection process, nature of award, and past recipients.

 

ISPOR BERNIE O’BRIEN NEW INVESTIGATOR AWARDS CALL FOR NOMINATIONS

 

The ISPOR Bernie O’Brien New Investigator Award was established in 2004 to honor the long-standing commitment of Bernie J. O’Brien, PhD to training and mentoring new scientists in the fields of outcomes research and pharmacoeconomics.  The award will be presented for the first time at the ISPOR 10th Annual International Meeting in Washington, DC, 15-18, 2005.

 

The ISPOR Awards Committee is seeking nominees for this award. See http://www.ispor.org/awards/Obrien_investigator.asp for descriptions, criteria, selection process, and nature of the award. The deadline to submit nominees for both awards is FEBRUARY 15, 2005.  Your nominations are encouraged!

 

HEALTH SCIENCE INITIATIVE: RCT-CEA TASK FORCE

 

For more details, please visit: http://www.ispor.org/workpaper/clinical_trial.asp

 

 

**NEW**ISPOR TASK FORCE: USING "REAL WORLD" DATA IN COVERAGE AND REIMBURSEMENT DECISIONS

 

Mission: To develop an analytic framework and action plan to assist health care decision-makers in dealing with “real world” data and information

 

Chair:  Peter Neumann ScD, Harvard School of Public Health, Harvard University, Boston, MA, USA

 

Working Group Chairs:

·        Clinical Outcomes Working Group

·        Chair: Deborah Marshall PhD, Innovus Research Inc.

·        Economic Outcomes Working Group

·        Chair: Lou Garrison PhD, University of Washington, Dept. of Pharmacy

·        Humanistic Outcomes Working Group

·        Chair: Penny Erickson PhD, O.L.G.A

·        Evidence Hierarchies Working Group

·       Chair: Dan Mullins PhD, University of Maryland, School of Pharmacy

 

For more details on this Task Force, please visit: http://www.ispor.org/workpaper/real_world_data.asp

 


  1. HOT TOPICS

Top

 

 

MEDICARE P&T COMMITTEES CAN CONSIDER COSTS, BUT ONLY IN BROAD CONTEXT

 

January 31, 2005 – Medicare prescription drug plan pharmacy & therapeutics committees must consider the overall economic impact of coverage decisions – not just pharmacy costs – if they use pharmacoeconomics data in their analyses, the Centers for Medicare & Medicaid Services states in its final rule implementing Title I of the Medicare Modernization Act.

 

For full text of the article, see: The Pink Sheet 2005;Jan 31:17-18.

 


 

  1. IMPORTANT DATES TO REMEMBER

Top

 

February 15, 2005 – Submission deadline for nominees for ISPOR Research Excellence Awards and Bernie J. O’Brien New Investigator Award.

 

April 19, 2005 – Early Meeting registration and hotel reservation deadline for the ISPOR 10th Annual International Meeting, Marriott Wardman Park Hotel, Washington, DC.

 

May 15-18 2005 ISPOR 10th Annual International Meeting, Marriott Wardman Park Hotel, Washington, DC.

 

June 20, 2005 Abstract Submission deadline for the ISPOR 8th Annual European Congress.


  1. EMPLOYMENT

Top

**NEW** 12 NEW POSITIONS AT THE ISPOR WEBSITE: Careers

 

 Advertise your positions on ISPOR Website (1 million hits per month)

 

FREE LISTING OF INTERNSHIPS

Visit ISPOR’s Internship-Professional Recruitment Assistance Program (I-PRAP) at

 

9 student resumes posted! I-PRAP is an ONLINE, FREE service available to ISPOR members. 

 

STUDENTS have the opportunity to search for internship positions available and post their CVs/resumes for employers to view. 

EMPLOYERS have the opportunity to post their Intern positions available and access CVs/resumes from interested students.

 

Any questions, please contact: iprap@ispor.org.

 

Statistical Scientist – Outcomes Research (Associate Director) With Pfizer

Position Available

 

Statistical Scientist – Outcomes Research (Associate Director)

 

Imagine a career that touches the lives of people everywhere.  Imagine an opportunity to reach beyond your area of expertise to make an impact on something greater than the bottom line.  Imagine playing a key role in some of the most critical issues facing healthcare today.  This is your career at Pfizer – a career unlike any other.

 

Partner with our Outcomes Research (OR) scientists to develop effective OR product support programs that make optimal use of available data sources and statistical methods.

Your contributions will provide technical statistical support to outcomes research projects and ensure sound statistical input to the development of health outcomes measurements, preparation of statistical analysis plans, interpretation of statistical results, and production of reporting displays for outcomes research projects.   You will also ensure that sound statistical principles are applied in Exploratory Data Analysis, data mining and meta-analysis of health outcomes databases.  This is an excellent opportunity to collaborate with Outcomes Research scientists and Biostatistics Therapeutic Area Heads to identify opportunities for exploratory analyses and data mining of health outcomes databases.  You will be expected to both communicate and collaborate with clinical project statisticians within the therapeutic areas to ensure consistency of statistical approaches and alignment of statistical analyses of health outcomes with overall product marketing strategy.

 

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status.  Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment.

 

For more details and to open the dialogue for consideration please go to: www.pfizer.com/careers and apply to requisition 039670.

 

  1. ISPOR MEMBERSHIP

Top


Update your email address at https://www.ispor.org/members/MemberProfile.aspx! Your email address is required as part of your log in information in the members only section of the ISPOR website.

 

 


eBulletin Index